Conclusively, our study provides new insights into the whole transcriptomic landscape of this highly aggressive neoplasia, which is distinct from other thyroid carcinomas, besides its frequently reported characteristic mutational burden, including TP53 or TERT-promoter mutations [1, 6, 7]. This evidence concerns the gene TP53 and neoplasm.